IL18 and small cell lung carcinoma: CAR T cells with the pro-inflammatory cytokine interleukin-18 (IL-18) significantly enhanced the efficacy of DLL3-targeted CAR T cell therapies in a SCLC model, and IL-18 also promoted the activation of CAR T cells and endogenous TILs in metastatic SCLC models in mice.